CCHT(SZ:000661)2023-03-30 08:11Financial Performance - The company achieved a revenue of CNY 12.627 billion in 2022, representing a year-on-year increase of 17.50% [3] - Net profit attributable to shareholders was CNY 4.140 billion, with a year-on-year growth of 10.18% [3] - JinSai Pharmaceutical reported a revenue of CNY 10.217 billion, up 25% year-on-year, and a net profit of CNY 4.217 billion, increasing by 14% [3] - BaiKe Bio's revenue decreased by 11% to CNY 1.071 billion, with a net profit drop of 25% to CNY 0.182 billion [3] - HuaKang Pharmaceutical's revenue remained stable at CNY 0.658 billion, with a net profit of CNY 0.031 billion, showing a decline [3] - High-Tech Real Estate reported a revenue of CNY 0.804 billion, a 20% increase, but net profit decreased [3] Research and Development - R&D investment reached CNY 1.663 billion in 2022, a 52% increase year-on-year [3] - The number of R&D personnel grew by 17% to 1,146 [3] Product Development - Growth hormone products saw new indications added in 2022, including for idiopathic short stature and Prader-Willi syndrome [4] - The company plans to enhance long-acting product revenue, which grew by approximately 60% [4] - New patient enrollment for growth hormone treatment is expected to increase by around 15% in Q1 2023 [5] Market Strategy - The company is focusing on divesting its real estate business to concentrate on its core biopharmaceutical operations [5] - The divestment aims to optimize asset structure and improve cash flow [5] - The company is actively participating in centralized procurement policies to ensure product coverage in relevant provinces [6] Vaccine Development - BaiKe Bio leads the market share in the varicella vaccine, contributing stable performance [7] - The nasal spray influenza vaccine's sales vary annually due to external factors, with efforts to increase sales and minimize waste [7] - The shingles vaccine is pending formal approval, with plans to expedite market entry once approved [7]